The closing price of Ocugen Inc (NASDAQ: OCGN) was $1.54 for the day, down -6.10% from the previous closing price of $1.64. In other words, the price has decreased by -$0.1000 from its previous closing price. On the day, 8808423 shares were traded.
Ratios:
Our analysis of OCGN’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.08 and its Current Ratio is at 5.08. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.08.
On August 23, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 14 ’23 when Zhang Junge bought 200,278 shares for $0.50 per share. The transaction valued at 99,999 led to the insider holds 1,077,182 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCGN now has a Market Capitalization of 395.01M and an Enterprise Value of 348.01M.
Stock Price History:
Over the past 52 weeks, OCGN has reached a high of $2.11, while it has fallen to a 52-week low of $0.34. The 50-Day Moving Average of the stock is 0.9376, while the 200-Day Moving Average is calculated to be 0.5836.
Shares Statistics:
OCGN traded an average of 7.80M shares per day over the past three months and 19.34M shares per day over the past ten days. A total of 256.50M shares are outstanding, with a floating share count of 250.87M. Insiders hold about 2.20% of the company’s shares, while institutions hold 10.22% stake in the company. Shares short for OCGN as of Mar 15, 2024 were 35.4M with a Short Ratio of 4.54, compared to 24.36M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 13.80% and a Short% of Float of 17.90%.
Earnings Estimates
The firm’s stock currently is rated by 2 analysts. On average, analysts expect EPS of -$0.06 for the current quarter, with a high estimate of -$0.06 and a low estimate of -$0.07, while EPS last year was -$0.1. The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.06 and low estimates of -$0.07.
Analysts are recommending an EPS of between -$0.28 and -$0.29 for the fiscal current year, implying an average EPS of -$0.28. EPS for the following year is -$0.28, with 2 analysts recommending between -$0.25 and -$0.31.
